NCT02388620View on ClinicalTrials.gov

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 25, 2015

Primary Completion Date

January 9, 2017

Study Completion Date

January 9, 2017

Conditions
Normal Hepatic FunctionImpaired Hepatic Function
Interventions
DRUG

LEE011

400 mg

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33124

University of Miami, Coral Gables

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY